| Similar Articles |
|---|
 |
The Motley Fool
July 25, 2008
Brian Orelli |
Affymetrix Astounds, in the Worst Way After taking a beating last quarter, biochip maker Affymetrix got pounded again in the second quarter, as its turnaround from the lows of 2006 fizzled out.   |
The Motley Fool
April 27, 2007
Brian Orelli |
Making Money Off Your Competitors Affymetrix is looking appealing with a few new products and potential revenues from an unlikely source. Investors, take note. |
The Motley Fool
February 6, 2008
Brian Orelli |
Insatiable Illumina Revenue is way up at Illumina, but can the company keep it going looking forward? |
The Motley Fool
July 25, 2007
Brian Orelli |
Shiny Happy Illumina Illumina, which makes chips that can distinguish one million different genes, announced another stellar quarter. That makes eight in a row. |
The Motley Fool
January 11, 2008
Brian Orelli |
Biochip Packaging: Some Settling May Occur Biochip maker Illumina settles its disputes about patents with Affymetrix. |
The Motley Fool
July 26, 2007
Brian Orelli |
Affymetrix Advances New products and services should help Affymetrix regain market share. Yesterday, the company even announced a small second-quarter profit. |
The Motley Fool
April 24, 2008
Brian Orelli |
Illumina Ignites This biochip maker is on fire. |
The Motley Fool
October 24, 2008
Brian Orelli |
Affymetrix Has Trouble Turning Around The problem is that Affymetrix doesn't sell sequencers, and no one seems to want the genome and RNA analyzers that it does sell. |
The Motley Fool
October 24, 2007
Brian Orelli |
Illumina's Illuminating Results There was stellar revenue growth, but margins and stock compensations pulled the bottom line down. |
The Motley Fool
November 12, 2008
Brian Orelli |
Affymetrix Gets Specific The biochip maker announces that it will acquire privately held Panomics for $73 million in cash. |
The Motley Fool
August 6, 2008
Brian Orelli |
Illumina Grabs Some Cash With biochip maker Illumina hitting 52-week highs, it seems inevitable that the company would do a secondary offering to grab some cash -- about $300 million, as it turns out. |
The Motley Fool
April 24, 2006
John Bluis |
Affymetrix Gets Chipped Again The woes continue for Affymetrix, the leading provider of high-density microarray products. Investors must decide if this is a management issue -- as indeed it appears to be. |
The Motley Fool
January 28, 2005
Karl Thiel |
Affymetrix Raking in the Chips The life sciences research chip maker is enjoying green pastures in the gene business. The company announced fourth-quarter revenues and profits that handily beat consensus expectations, and then gave an upbeat view of 2005. |
The Motley Fool
October 28, 2009
Brian Orelli |
Ugly, but Still Built for Growth It continues to be a tale of two business segments for Illumina, with sales from the consumables used in its sequencing machines more than doubling, while its array business remains down considerably. |
The Motley Fool
July 22, 2009
Brian Orelli |
Levering the Genome Lower revenue can't stop Illumina from turning in a good bottom line. |
The Motley Fool
April 25, 2008
Brian Orelli |
Affymetrix Learns About Inertia Slower sales of its older chips drag down growth. |
The Motley Fool
January 31, 2006
John Bluis |
Affymetrix: Far, Far Array Investors who enjoy companies that are consistent with guidance may have some interest in this company that provides tools for use in genomics-related research. Unfortunately, this year the consistency was in reporting disappointing results. |
The Motley Fool
July 24, 2008
Brian Orelli |
Illumina Polishes Its Biochips There's very little to complain about in Illumina's earnings report. In this market, you'll see few investors grumbling about double-digit growth. |
The Motley Fool
July 12, 2011
Brian Orelli |
Ducks in Order; Now Let's See Some Data Sequenom is getting all its ducks in a row in preparation for launching its SensiGene Trisomy 21 laboratory-developed test. |
The Motley Fool
April 27, 2011
Brian Orelli |
Illuminating the Growth Competition in the DNA sequencing market may be heating up, but 47% growth for Illumina isn't too shabby. |
Wired
June 2000
Brian Alexander |
Biopoly Money Patents and strong-arm tactics are helping make Affymetrix the Intel of biochips. Along the way, Affy wants to turn DNA into a proprietary system. |
The Motley Fool
February 8, 2010
Brian Orelli |
An Earnings Surprise of an Unusual Kind Illumina beats management's own preliminary revenue announcement. |
The Motley Fool
January 3, 2012
Alex Planes |
Another Entry in the Genome Patent Rumble There's a whole lot of lawsuits going on. |
The Motley Fool
February 4, 2009
Brian Orelli |
43% Growth! Yee-Haw! Illumina rocks another quarter. |
The Motley Fool
August 7, 2006
Stephen D. Simpson |
Affymetrix: Price Always Matters Affymetrix has legit technology, but that doesn't mean it has infinite value for investors. |
Chemistry World
November 21, 2013
Phillip Broadwith |
Rapid DNA sequencing cleared for the clinic The approval covers Illumina's MiSeqDx instrument, together with two diagnostic assay kits for cystic fibrosis that run on it, and a kit that allows clinical labs to develop their own diagnostic tests. |
The Motley Fool
June 13, 2008
Brian Orelli |
China Medical Passes the Test China Medical's revenue was up an impressive 74% year over year. |
Bio-IT World
February 11, 2005
Robert M. Frederickson |
Genomics Drives New Crop of IVDs In vitro diagnostic microarrays are an important tool in oncology. The Affymetrix GeneChip System 3000Dx (GCS 3000Dx) was the first microarray instrument to be cleared by the FDA for IVD use. |
The Motley Fool
July 28, 2010
Brian Orelli |
Now There's an Illuminating Idea Helping your customers sell more of your product makes a lot of sense. |
Bio-IT World
July 14, 2004
Malorye A. Branca |
The Maven of Microarrays Affymetrix Research Institute's CEO, Stephen Fodor, discusses building a tech business without a blueprint |
The Motley Fool
September 28, 2005
Stephen D. Simpson |
Affymetrix Stumbles Again Though the company was one of the only genomics plays to escape the bubble with a real business and a solid market cap, Affymetrix's stock seemed poised to take a serious hit Wednesday for the second time in about three months. |
Bio-IT World
February 2007
Robert M. Frederickson |
Scramble for CodeLink Customers GE Healthcare has quietly announced that it will stop production of the popular CodeLink array system in 2007. The news was not a complete surprise to some users of the system who felt the company had been backing away from the platform. |
The Motley Fool
April 22, 2009
Brian Orelli |
Illuminating Stock Option Problems Illumina's stock options are getting a little ridiculous. This problem was pointed out in the third quarter last year, and it doesn't seem to be going away. |
The Motley Fool
July 23, 2011 |
Affymetrix Earnings Preview Affymetrix will unveil its latest earnings on Wednesday, July 27. |
Bio-IT World
July 2005
Johan Bostrom |
Affymetrix to Acquire ParAllele The companies have been working together for the past two years, with Affymetrix using ParAllele's assay technology with the Affymetrix GeneChip technology. Affymetrix expects to strengthen its assay R&D capabilities and add knowledge in specific assay capabilities through the acquisition. |
The Motley Fool
June 14, 2010
Bruce Bigelow |
Genetic Testing Companies in San Diego, Boston, and San Francisco Studying FDA Letters The letters notify the companies that genome-sequencing tests they offer to consumers are medical devices that require the agency's approval. |
BusinessWeek
February 20, 2006
Gene G. Marcial |
Fast Growth At Illumina Is In The Genes The company has become a rising star in the complex analysis of gene variation, and the stock shows it. |
